reteplase

Also known as BM 06.022, t-plasminogen activator, Tissue-type plasminogen activator precursor, t- PA, tPA

Reteplase, trade names include Retavase, is a thrombolytic drug, used to treat heart attacks by breaking up the clots that cause them.

Key facts

Drug.verifiedrevid: 464381256
Drug.tradename: Retavase, Retefuse, Rapilysin, Mirel, others
Drug.licence_EU: yes
Drug.ChemSpiderID: none
Drug.CAS_number: 133652-38-7
Drug.ATC_prefix: B01
Drug.ATC_suffix: AD07
Drug.DrugBank: DB00015
Drug.UNII: DQA630RIE9
Drug.KEGG: D05721
Drug.C: 1736
Drug.H: 2671
Drug.N: 499
Drug.O: 522
Drug.S: 22

via Wikipedia infobox

Research

553 papers

Reteplase versus Alteplase for Acute Ischemic Stroke.The New England journal of medicine · 2024
Reteplase: Structure, Function, and Production.Advanced biomedical research · 2019
Reteplase versus alteplase for acute ischemic stroke: Meta-analysis.The American journal of emergency medicine · 2025
Safety and Efficacy of Reteplase Versus Alteplase for Acute Ischemic Stroke: A Phase 2 Randomized Controlled Trial.Stroke · 2024
Patency trials with reteplase (r-PA): what do they tell us?The American journal of cardiology · 1996

via PubMed

~1 min read

Article

1 sections

Contents

References

Reteplase, trade names include Retavase, is a thrombolytic drug, used to treat heart attacks by breaking up the clots that cause them.

Reteplase is a recombinant non-glycosylated form of human tissue plasminogen activator, which has been modified to contain 357 of the 527 amino acids of the original protein. It is produced in the bacterium Escherichia coli. Reteplase was approved for use in 1996.